- 4.4Impact Factor
- 8.8CiteScore
- 21 daysTime to First Decision
Special Issues
Cancers publishes Special Issues to create collections of papers on specific topics, with the aim of building a community of authors and readers to discuss the latest research and develop new ideas and research directions. Special Issues are led by Guest Editors, who are experts on the topic and all Special Issue submissions follow MDPI's standard editorial process.
The journal’s Editor-in-Chief and/or designated Editorial Board Member will oversee Guest Editor appointments and Special Issue proposals, checking their content for relevance and ensuring the suitability of the material for the journal. The papers published in a Special Issue will be collected and displayed on a dedicated page of the journal’s website. Further information on MDPI's Special Issue polices and Guest Editor responsibilities can be found here. For any inquiries related to a Special Issue, please contact the Editorial Office.
Advances in Adoptive Cell Therapy for Cancer
Deadline: 30 November 2026
Update in Pathology of Gynaecologic Cancer
Deadline: 30 November 2026
Innovations and Current Evidence in Radiotherapy for Urological Cancers
Deadline: 30 November 2026
HMGA Oncoproteins in Cancer
Deadline: 30 November 2026
Infectious Pathogens and Cancer
Deadline: 25 November 2026
Treatment and Prognosis of Pediatric Medulloblastoma
Deadline: 25 November 2026
Radiologic Staging and Surgical Decision-Making in the Era of Neoadjuvant Therapy for Breast Cancer
Deadline: 25 November 2026
Cancer Cells Fostered Microenvironment in Metastasis (2nd Edition)
Deadline: 25 November 2026
The Pathologic Diagnosis and Clinical Therapy of Neuroendocrine Tumors: 2nd Edition
Deadline: 20 November 2026
Evaluating the Clinical Impact of Robotic Surgery in the Management of Colorectal Cancer
Deadline: 15 November 2026
Recent Advances in Endoscopic, Metabolomic, and Ultrasound Approaches to Gastrointestinal, Hepatic, and Pancreatic Tumors
Deadline: 15 November 2026
Novel Insights into Glioma Immunotherapy
Deadline: 5 November 2026
of 262

